問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaohsiung Municipal Gangshan Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 820Kaohsiung CityKaohsiung Gangshan

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

121Cases

2018-04-25 - 2023-07-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Ustekinumab (STELARA)

Participate Sites
10Sites

Terminated8Sites

張棋楨
Taipei Medical University Hospital

羅淑芬
Linkou Chang Gung Medical Foundation

2016-05-04 - 2020-10-31

Phase II

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT TRIAL OF AC-201 CONTROLLED RELEASE TABLETS IN SUBJECTS WITH HEMOPHILIC ARTHROPATHY

  • Condition/Disease

    HEMOPHILIC ARTHROPATHY

  • Test Drug

    AC-201CR

Participate Sites
6Sites

Terminated5Sites

張家堯
Taipei Medical University Hospital

Division of Hematology & Oncology

邱世欣
Kaohsiung Municipal Gangshan Hospital

未分科

2016-01-01 - 2019-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis

  • Condition/Disease

    Ankylosing Spondylitis

  • Test Drug

    ENIA11

Participate Sites
10Sites

Not yet recruiting7Sites

Suspended2Sites

2016-12-31 - 2023-12-31

Phase III

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

  • Condition/Disease

    Prodromal Alzheimer's Disease

  • Test Drug

    Solanezumab (LY2062430)

Participate Sites
10Sites

Terminated9Sites

2017-06-01 - 2019-12-31

Phase III

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    Elenbecestat (E2609)

Participate Sites
13Sites

Terminated11Sites

胡朝榮
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

2017-06-01 - 2019-12-31

Phase II/III

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

  • Condition/Disease

    Advanced or Metastatic Biliary Tract Cancer

  • Test Drug

    Varlitinib

Participate Sites
7Sites

Terminated5Sites

白禮源
China Medical University Hospital-Taipei

未分科

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-05-01 - 2025-12-31

Others

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    CVC /150mg tablet

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting1Sites

Terminated1Sites

彭成元
China Medical University Hospital-Taipei

未分科

2017-12-01 - 2019-12-31

Phase III

Multi-center, partially blinded, randomized, 24-week, parallel grouping, non-inferiority, open-label, active controlled trial, comparing the efficacy and safety of QVM149 with salmeterol/fluticasone + tiotropium triple combination therapy for patients with poorly controlled asthma

  • Condition/Disease

    Asthma

  • Test Drug

    QVM149

Participate Sites
9Sites

Terminated7Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

杭良文
China Medical University Hospital-Taipei

未分科

2018-03-07 - 2022-08-15

Phase III

A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis

  • Condition/Disease

    Active Ankylosing Spondylitis

  • Test Drug

    AIN457

Participate Sites
6Sites

Terminated5Sites

2017-05-01 - 2020-03-04

Phase II

A randomized, double blind, placebo controlled multicenter Phase 2 doseranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjögren’s syndrome

  • Condition/Disease

    Sjögren’s syndrome

  • Test Drug

    VAY736

Participate Sites
7Sites

Terminated5Sites

藍忠亮
China Medical University Hospital

藍忠亮
China Medical University Hospital-Taipei

未分科

1 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB